Protein SUMOylation, an emerging pathway in amyotrophic lateral sclerosis

International Journal of Neuroscience

Volumn 123, Issue 6, 2013, Pages 366-374

  Dangoumau, Audrey ^a   Veyrat Durebex, Charlotte ^a,b   Blasco, Hélène ^a,b   Praline, Julien ^a,c   Corcia, Philippe ^a,c   Andres, Christian R ^a,b   Vourc'H, Patrick ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b Service de Biochimie et de Biologie Moléculaire   (France)

^c UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

ALS; Hypoxia; Oxidative stress; SUMO; Ubiquitin

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; EXCITATORY AMINO ACID TRANSPORTER 2; FUSED IN SARCOMA PROTEIN; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; PROTEASOME; TAR DNA BINDING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DISEASE ASSOCIATION; ENZYME ACTIVITY; EXCITOTOXICITY; HUMAN; HYPOXIA; OXIDATIVE STRESS; SUMOYLATION;

AMYOTROPHIC LATERAL SCLEROSIS; DNA-BINDING PROTEINS; HUMANS; NERVE TISSUE PROTEINS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SUMOYLATION; SUPEROXIDE DISMUTASE; UBIQUITINATION;

EID: 84878086454     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2012.761984     Document Type: Article

References (95)

1. Hardiman O, Van den Berg LH, Kiernan MC. Clinicaldiagnosis and management of amyotrophic lateral sclerosis. NatRev Neurol 2011;7(11):639-49.
2. Fei E, Jia N, Yan M, et al. SUMO-1 modification increaseshuman SOD1 stability and aggregation. Biochem Biophys ResCommun 2006;347(2):406-12.
3. Seyfried NT, Gozal YM, Dammer EB, et al. Multiplex SILACanalysis of a cellular TDP-43 proteinopathy model reveals proteininclusions associated with SUMOylation and diversepolyubiquitin chains. Mol Cell Proteomics 2010;9(4):705-18.
4. Oh S-M, Liu Z,Okada M, et al. Ebp1 sumoylation, regulated byTLS/FUS E3 ligase, is required for its anti-proliferative activity.Oncogene 2010;29(7):1017-30.
5. Kwiatkowski TJ Jr, Bosco DA, Leclerc AL, et al. Mutationsin the FUS/TLS gene on chromosome 16 cause familial amyotrophiclateral sclerosis. Science 2009;323(5918):1205-8.
6. Vance C, Rogelj B, Hortob́agyi T, et al. Mutations in FUS, anRNA processing protein, cause familial amyotrophic lateral sclerosistype 6. Science 2009;323(5918):1208-11.
7. Brown JA, Min J, Staropoli JF, et al. SOD1, ANG, TARDBPand FUS mutations in amyotrophic lateral sclerosis: a UnitedStates clinical testing lab experience. Amyotroph Lateral Scler2012;13(2):217-22.
8. Xu R, Wu C, Zhang X, et al. Linking hypoxic and oxidativeinsults to cell death mechanisms in models of ALS. Brain Res2011;1372:133-44.
9. Bohren KM, Nadkarni V, Song JH, et al. A M55V polymorphismin a novel SUMO gene (SUMO-4) differentiallyactivates heat shock transcription factors and is associatedwith susceptibility to type I diabetes mellitus. J Biol Chem2004;279(26):27233-8.
10. Lapenta V, Chiurazzi P, Van der Spek P, et al. SMT3A, ahuman homologue of the S. cerevisiae SMT3 gene, maps tochromosome 21qter and defines a novel gene family. Genomics1997;40(2):362-6.
11. Lee JH, Park SM, Kim OS, et al. Differential SUMOylationof LXRalpha and LXRbeta mediates transrepression of STAT1inflammatory signaling in IFN-gamma-stimulated brain astrocytes.Mol Cell 2009;35(6):806-17.
12. Craig TJ, Henley JM. Protein SUMOylation in spine structureand function. Curr Opin Neurobiol 2012;22(3):480-7.
13. Tatham MH, Jaffray E, Vaughan OA, et al. Polymeric chains ofSUMO-2 and SUMO-3 are conjugated to protein substrates bySAE1/SAE2 and Ubc9. J Biol Chem 2001;276(38):35368-74.
14. Matic I, Van Hagen M, Schimmel J, et al. In vivo identificationof human small ubiquitin-like modifier polymerization sites byhigh accuracy mass spectrometry and an in vitro to in vivo strategy.Mol Cell Proteomics 2008;7(1):132-44.
15. Gong L, Li B, Millas S, Yeh ET. Molecular cloningand characterization of human AOS1 and UBA2, componentsof the sentrin-activating enzyme complex. FEBS Lett1999;448(1):185-9.
16. Johnson ES, Blobel G. Ubc9p is the conjugating enzymefor the ubiquitin-like protein Smt3p. J Biol Chem1997;272(43):26799-802.
17. Michelle C, Vourc'h P, Mignon L, Andres CR. What was theset of ubiquitin and ubiquitin-like conjugating enzymes in theeukaryote common ancestor? J Mol Evol 2009;68(6):616-28.
18. Rodriguez MS, Desterro JM, Lain S, et al. SUMO-1 modificationactivates the transcriptional response of p53. EMBO J1999;18(22):6455-61.
19. Sampson DA, Wang M, Matunis MJ. The small ubiquitinlikemodifier-1 (SUMO-1) consensus sequence mediates Ubc9binding and is essential for SUMO-1 modification. J Biol Chem2001;276(24):21664-9.
20. Hietakangas V, Anckar J, Blomster HA, et al. PDSM, a motiffor phosphorylation-dependent SUMO modification. Proc NatlAcad Sci USA 2006;103(1):45-50.
21. Zheng Z, Cai C, Omwancha J, et al. SUMO-3 enhances androgenreceptor transcriptional activity through a sumoylationindependentmechanism in prostate cancer cells. J Biol Chem2006;281(7):4002-12.
22. Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modificationof IkappaBalpha inhibits NF-kappaB activation. Mol Cell1998;2(2):233-9.
23. Pramatarova A, Laganìere J, Roussel J, et al. Neuronspecificexpression of mutant superoxide dismutase 1 in transgenicmice does not lead to motor impairment. J Neurosci2001;21(10):3369-74.
24. Picard N, Caron V, Bilodeau S, et al. Identification of estrogenreceptor ? as a SUMO-1 target reveals a novel phosphorylatedsumoylation motif and regulation by glycogen synthase kinase3?. Mol Cell Biol 2012;32(14):2709-21.
25. Das A, Smith JA, Gibson C, et al. Estrogen receptor agonistsand estrogen attenuate TNF-?-induced apoptosis in VSC4.1motoneurons. J Endocrinol 2011;208(2):171-82.
26. Meulmeester E, Kunze M, Hsiao HH, et al. Mechanism andconsequences for paralog-specific sumoylation of ubiquitinspecificprotease 25. Mol Cell 2008;30(5):610-9.
27. Knipscheer P, Flotho A, Klug H, et al. Ubc9 sumoylationregulates SUMO target discrimination. Mol Cell2008;31(3):371-82.
28. Gomes C, Escrevente C, Costa J. Mutant superoxide dismutase1 overexpression in NSC-34 cells: effect of trehalose on aggregation,TDP-43 localization and levels of co-expressed glycoproteins.Neurosci Lett 2010;475(3):145-9.
29. Zhou W, Ryan JJ, Zhou H. Global analyses of sumoylated proteinsin Saccharomyces cerevisiae. Induction of protein sumoylationby cellular stresses. J Biol Chem 2004;279(31):32262-8.
30. Wang I-F, Reddy NM, Shen C-KJ. Higher order arrangementof the eukaryotic nuclear bodies. Proc Natl Acad Sci USA2002;99(21):13583-8.
31. Mukhopadhyay D, Ayaydin F, Kolli N, et al. SUSP1 antagonizesformation of highly SUMO2/3-conjugated species. J CellBiol 2006;174(7):939-49.
32. Vertegaal ACO, Ogg SC, Jaffray E, et al. A proteomic study ofSUMO-2 target proteins. J Biol Chem 2004;279(32):33791-8.
33. Golebiowski F, Matic I, Tatham MH, et al. System-widechanges to SUMO modifications in response to heat shock. SciSignal 2009;2(72):ra24.
34. Ren J, Gao X, Jin C, et al. Systematic study of protein sumoylation:development of a site-specific predictor of SUMOsp 2.0.Proteomics 2009;9(12):3409-12.
35. Ferraiuolo L, Kirby J, Grierson AJ, et al.Molecular pathways ofmotor neuron injury in amyotrophic lateral sclerosis. Nat RevNeurol 2011;7(11):616-30.
36. Navascues J, Bengoechea R, Tapia O, et al. SUMO-1 transientlylocalizes to Cajal bodies in mammalian neurons. J Struct Biol2008;163(2):137-46.
37. Ranganathan S, Bowser R. p53 and cell cycle proteins participatein spinal motor neuron cell death in ALS. Open Pathol J2010;4:11-22.
38. Martin S, Wilkinson KA, Nishimune A, Henley JM. Emergingextranuclear roles of protein SUMOylation in neuronal functionand dysfunction. Nat Rev Neurosci 2007;8(12):948-59.
39. Datwyler AL, L̈attig-T ̈unnemann G, Yang W, et al. SUMO2/3conjugation is an endogenous neuroprotective mechanism.J Cereb Blood Flow Metab 2011;31(11):2152-9.
40. Greenway MJ, Andersen PM, Russ C, et al. ANG mutationssegregate with familial and sporadic amyotrophic lateralsclerosis. Nat Genet 2006;38(4):411-3.
41. Paubel A, Violette J, Amy M, et al. Mutations of the ANG genein French patients with sporadic amyotrophic lateral sclerosis.Arch Neurol 2008;65(10):1333-6.
42. Carbia-Nagashima A, Gerez J, Perez-Castro C, et al. RSUME,a small RWD-containing protein, enhances SUMO conjugationand stabilizes HIF-1alpha during hypoxia. Cell2007;131(2):309-23.
43. Kang S, Hong S. SUMO-1 interacts with mutant ataxin-1 andcolocalizes to its aggregates in Purkinje cells of SCA1 transgenicmice. Arch Ital Biol 2010;148(4):351-63.
44. Cheng J, Kang X, Zhang S, Yeh ETH. SUMO-specific protease1 is essential for stabilization of HIF1alpha during hypoxia. Cell2007;131(3):584-95.
45. Agbor TA, Cheong A, Comerford KM, et al. Small ubiquitinrelatedmodifier (SUMO)-1 promotes glycolysis in hypoxia.J Biol Chem 2011;286(6):4718-26.
46. Giorgino F, De Robertis O, Laviola L, et al. The sentrinconjugatingenzyme mUbc9 interacts with GLUT4 andGLUT1 glucose transporters and regulates transporter levelsin skeletal muscle cells. Proc Natl Acad Sci USA2000;97(3):1125-30.
47. Sato K, Morimoto N, Kurata T, et al. Impaired response ofhypoxic sensor protein HIF-1? and its downstream proteinsin the spinal motor neurons of ALS model mice. Brain Res2012;1473:55-62.
48. Baillet A, Chanteperdrix V, Trocḿe C, et al. The role of oxidativestress in amyotrophic lateral sclerosis and Parkinson's disease.Neurochem Res 2010;35(10):1530-7.
49. Temṕe D, Piechaczyk M, Bossis G. SUMO under stress.Biochem Soc Trans 2008;36(Pt 5):874-8.
50. KuoM-L, Den BestenW, ThomasMC, Sherr CJ. Arf-inducedturnover of the nucleolar nucleophosmin-associated SUMO-2/3protease Senp3. Cell Cycle 2008;7(21):3378-87.
51. Girdwood D, Bumpass D, Vaughan OA, Thain A, et al. P300transcriptional repression is mediated by SUMO modification.Mol Cell 2003;11(4):1043-54.
52. Huang X, Ding L, Bennewith KL, et al. Hypoxia-induciblemir-210 regulates normoxic gene expression involved in tumorinitiation. Mol Cell 2009;35(6):856-67.
53. Bossis G, Melchior F. Regulation of SUMOylation by reversibleoxidation of SUMO conjugating enzymes. Mol Cell2006;21(3):349-57.
54. Koh S-H, Lee Y-B, Kim KS, et al. Role of GSK-3beta activityin motor neuronal cell death induced by G93A or A4V mutanthSOD1 gene. Eur J Neurosci 2005;22(2):301-9.
55. Ahn S-W, Kim J-E, Park KS, et al. The neuroprotective effect ofthe GSK-3? inhibitor and influence on the extrinsic apoptosisin the ALS transgenic mice. J Neurol Sci 2012;320(1-2):1-5.
56. Crippa V, Sau D, Rusmini P, et al. The small heat shock proteinB8 (HspB8) promotes autophagic removal of misfoldedproteins involved in amyotrophic lateral sclerosis (ALS). HumMol Genet 2010;19(17):3440-56.
57. Yan S, Sun X, Xiang B, et al. Redox regulation of the stabilityof the SUMO protease SENP3 via interactions with CHIP andHsp90. EMBO J 2010;29(22):3773-86.
58. Van den Bosch L. [The causes and mechanism of selective motorneuron death in amyotrophic lateral sclerosis]. Verh K AcadGeneeskd Belg 2006;68(4):249-69.
59. Foran E, Bogush A, Goffredo M, et al. Motor neuron impairmentmediated by a sumoylated fragment of the glial glutamatetransporter EAAT2. Glia 2011;59(11):1719-31.
60. Maruyama H, Morino H, Ito H, et al. Mutations of optineurinin amyotrophic lateral sclerosis. Nature 2010;465(7295):223-6.
61. Boston-Howes W, Gibb SL, Williams EO, et al. Caspase-3cleaves and inactivates the glutamate transporter EAAT2. J BiolChem 2006;281(20):14076-84.
62. Gibb SL, Boston-Howes W, Lavina ZS, et al. A caspase-3-cleaved fragment of the glial glutamate transporter EAAT2 issumoylated and targeted to promyelocytic leukemia nuclearbodies in mutant SOD1-linked amyotrophic lateral sclerosis.J Biol Chem 2007;282(44):32480-90.
63. Docagne F, Nicole O, Gabriel C, et al. Smad3-dependent inductionof plasminogen activator inhibitor-1 in astrocytes mediatesneuroprotective activity of transforming growth factorbeta1 against NMDA-induced necrosis. Mol Cell Neurosci2002;21(4):634-44.
64. Nakamura M, Ito H, Wate R, et al. Phosphorylated Smad2/3immunoreactivity in sporadic and familial amyotrophic lateralsclerosis and its mouse model. Acta Neuropathol2008;115(3):327-34.
65. Imoto S, Ohbayashi N, Ikeda O, et al. Sumoylation of Smad3stimulates its nuclear export during PIASy-mediated suppressionof TGF-beta signaling. Biochem Biophys Res Commun2008;370(2):359-65.
66. Nakamura M, Kaneko S, Ito H, et al. Activation of transforminggrowth factor-?/Smad signaling reduces aggregate formation ofmislocalized TAR DNA-binding protein-43. Neurodegener Dis2012. [Epub before print] DOI 10.1159/000338151.
67. Gordon PH, Meininger V. How can we improve clinicaltrials in amyotrophic lateral sclerosis? Nat Rev Neurol2011;7(11):650-4.
68. Raoul C, Buhler E, Sadeghi C, et al. Chronic activation inpresymptomatic amyotrophic lateral sclerosis (ALS) mice of afeedback loop involving Fas, Daxx, and FasL. Proc Natl AcadSci USA 2006;103(15):6007-12.
69. Lin D-Y, Huang Y-S, Jeng J-C, et al. Role of SUMO-interactingmotif in Daxx SUMO modification, subnuclear localization,and repression of sumoylated transcription factors. Mol Cell2006;24(3):341-54.
70. Shin EJ, Shin HM, Nam E, et al. DeSUMOylating isopeptidase:a second class of SUMO protease. EMBO Rep2012;13(4):339-46.
71. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Znsuperoxide dismutase gene are associated with familial amyotrophiclateral sclerosis. Nature 1993;362:59-62.
72. Greenway MJ, Andersen PM, Russ C, et al. ANG mutationssegregate with familial and "sporadic" amyotrophic lateral sclerosis.Nat Genet 2006;38:411-3.
73. Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutationsin familial and sporadic amyotrophic lateral sclerosis. Science2008;3191668-72.
74. Maruyama H, Morino H, Ito H, et al. Mutations of optineurinin amyotrophic lateral sclerosis. Nature 2010;465:223-6.
75. Deng H-X, Chen W, Hong S-T, et al. Mutations in UBQLN2cause dominant X-linked juvenile and adult-onset ALS andALS/dementia. Nature 2011;477:211-5.
76. Yang Y, Hentati A, Deng HX, et al. The gene encoding alsin, aprotein with three guanine-nucleotide exchange factor domains,is mutated in a form of recessive amyotrophic lateral sclerosis.Nat Genet 2001;29:160-5.
77. Chen Y-Z, Bennett CL, Huynh HM, et al. DNA/RNA helicasegene mutations in a form of juvenile amyotrophic lateral sclerosis(ALS4). Am J Hum Genet 2004;74:1128-35.
78. Orlacchio A, Babalini C, Borreca A, et al. SPATACSIN mutationscause autosomal recessive juvenile amyotrophic lateralsclerosis. Brain 2010;133:591-8.
79. Nishimura AL, Mitne-Neto M, Silva HCA et al. A mutationin the vesicle-trafficking protein VAPB causes late-onset spinalmuscular atrophy and amyotrophic lateral sclerosis. Am J HumGenet 2004;75:822-31.
80. Chow CY, Landers JE, Bergren SK, et al. Deleterious variantsof FIG4, a phosphoinositide phosphatase, in patients with ALS.Am J Hum Genet 2009;84:85-8.
81. Luty AA, Kwok JBJ, Dobson-Stone C, et al. Sigma nonopioidintracellular receptor 1 mutations cause frontotemporallobar degeneration-motor neuron disease. Ann Neurol2010;68:639-49.
82. Al-Saif A, Al-Mohanna F, Bohlega S. A mutation in sigma-1 receptorcauses juvenile amyotrophic lateral sclerosis. Ann Neurol2011;70:913-9.
83. Renton AE, Majounie E, Waite A, et al. A hex nucleotide repeatexpansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011;72:257-68.
84. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. ExpandedGGGGCC hex nucleotide repeat in noncoding regionof C9ORF72 causes chromosome 9p-linked FTD and ALS.Neuron 2011;72:245-56.
85. Hutton M, Lendon CL, Rizzu P, et al. Association of missenseand 5'-splice-site mutations in tau with the inherited dementiaFTDP-17. Nature 1998;393:702-5.
86. Johnson JO, Mandrioli J, Benatar M, et al. Exome sequencingreveals VCP mutations as a cause of familial ALS. Neuron2010;68:857-64.
87. Búee L, Ṕerez-Tur J, Leveugle B, et al. ApolipoproteinE in Guamanian amyotrophic lateral sclerosis/parkinsonismdementiacomplex: genotype analysis and relationships toneuropathological changes. Acta Neuropathol 1996;91:247-53.
88. Elden AC, Kim H-J, Hart MP, et al. Ataxin-2 intermediatelengthpolyglutamine expansions are associated with increasedrisk for ALS. Nature 2010;466:1069-75.
89. Gros-Louis F, Andersen PM, Dupre N, et al. ChromograninB P413L variant as risk factor and modifier of disease onsetfor amyotrophic lateral sclerosis. Proc Natl Acad Sci USA2009;106:21777-82.
90. Parkinson N, Ince PG, Smith MO, et al. ALS phenotypes withmutations in CHMP2B (charged multivesicular body protein2B). Neurology 2006;67:1074-7.
91. Saeed M, Siddique N, Hung WY, et al. Paraoxonase clusterpolymorphisms are associated with sporadic ALS. Neurology2006;67:771-6.
92. Blasco H, Vourc'h P, Nadjar Y, et al. Association between divalentmetal transport 1 encoding gene (SLC11A2) and diseaseduration in amyotrophic lateral sclerosis. J Neurol Sci2011;303:124-7.
93. Corcia P, Mayeux-Portas V, Khoris J, et al. Abnormal SMN1gene copy number is a susceptibility factor for amyotrophic lateralsclerosis. Ann Neurol 2002;51:243-6.
94. Veldink JH, van den Berg LH, Cobben JM, et al. Homozygousdeletion of the survival motor neuron 2 gene isa prognostic factor in sporadic ALS. Neurology 2001;56:749-52.
95. van Es MA, Veldink JH, Saris CGJ, et al. Genome-wide associationstudy identifies 19p13.3 (UNC13A) and 9p21.2 assusceptibility loci for sporadic amyotrophic lateral sclerosis. NatGenet 2009;41:1083-7.